Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-01-2018 | Retinal Disorders

AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration

Authors: Yoichi Sakurada, Wataru Kikushima, Atsushi Sugiyama, Seigo Yoneyama, Naohiko Tanabe, Mio Matsubara, Hiroyuki Iijima

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 1/2018

Abstract

Purpose

To investigate whether the severity of the condition in the untreated fellow eye is a predictive factor for the response to intravitreal aflibercept injection (IAI) for exudative age-related macular degeneration (AMD).

Methods

A retrospective medical chart review was conducted for 88 patients with treatment-naïve neovascular AMD, who were initially treated with three monthly IAIs, followed by monthly monitoring and re-injection as needed for at least 12 months. Subjects were classified into three groups according to the severity of the condition in their untreated eye, based on the severity scale in the Age-Related Eye Disease Study (AREDS): group 0, AREDS severity level 1 (no drusen); group 1, AREDS severity level 2 or 3 (any drusen); group 2, AREDS severity level 4 (advanced AMD). Genotyping was performed in all cases for ARMS2 A69S and CFH I62V.

Results

Fellow-eye severity was associated with age and the risk variant of ARMS2 A69S (P = 0.005 and 0.001, respectively). Although best-corrected visual acuity (BCVA) had improved significantly after 12 months in all groups, this improvement was significantly greater in group 0 than in the other groups (P = 0.008). The retreatment-free period was also significantly longer for group 0 than for the other groups (P = 0.016), and the number of additional injections was significantly associated with fellow-eye severity (P = 0.007).

Conclusions

Fellow-eye severity was associated with treatment response in terms of visual improvement and retreatment and may be a predictive factor for response to IAI for neovascular AMD.

Kume A, Ohshiro T, Sakurada Y, Kikushima W, Yoneyama S, Kashiwagi K (2016) Treatment patterns and health care costs for age-related macular degeneration in Japan: an analysis of national insurance claims data. Ophthalmology 123:1263–1268. https://doi.org/10.1016/j.ophtha.2016.01.042 CrossRefPubMed

Ferrara N (2009) VEGF-A: a critical regulator of blood vessel growth. Eur Cytokine Netw 20:158–163. https://doi.org/10.1684/ecn.2009.0170 PubMed

Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, Sy JP, Schneider S, for the ANCHOR Study Group (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444. https://doi.org/10.1056/NEJMoa062655

Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY, for the MARINA Study Group (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431. https://doi.org/10.1056/NEJMoa054481

Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U, VIEW 1 and VIEW 2 Study Groups (2012) Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548. https://doi.org/10.1016/j.ophtha.2012.09.006 CrossRefPubMed

Finger RP, Wickremasinghe SS, Baird PN, Guymer RH (2014) Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration. Surv Ophthalmol 59:1–18. https://doi.org/10.1016/j.survophthal.2013.03.009 CrossRefPubMed

Kang HM, Kwon HJ, Yi JH, Lee CS, Lee SC (2014) Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Am J Ophthalmol 157:1013–1021. https://doi.org/10.1016/j.ajo.2014.01.019 CrossRefPubMed

Kikushima W, Sakurada Y, Sugiyama A, Tanabe N, Kume A, Iijima H (2016) Factors predictive of visual outcome 1 year after intravitreal aflibercept injection for typical neovascular age-related macular degeneration. J Ocul Pharmacol Ther 32:376–382. https://doi.org/10.1089/jop.2015.0125 CrossRefPubMed

Age-Related Eye Disease Study Research Group (1999) The Age-Related Eye Disease Study (AREDS): design implications. AREDS report no. 1. Control Clin Trials 20:573–600CrossRef

10.

Ferris FL, Davis MD, Clemons TE, Lee LY, Chew EY, Lindblad AS, Milton RC, Bressler SB, Klein R, Age-Related Eye Disease Study Research Group (2005) A simplified severity scale for age-related macular degeneration: AREDS report no. 18. Arch Ophthalmol 123:1570–1574. https://doi.org/10.1001/archopht.123.11.1570 CrossRefPubMed

11.

Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kikushima W, Mabuchi F, Kume A, Kubota T, Iijima H (2016) Prevalence and genetic characteristics of geographic atrophy among elderly Japanese with age-related macular degeneration. PLoS One 11:e0149978. https://doi.org/10.1371/journal.pone.0149978 CrossRefPubMedPubMedCentral

12.

Klein R, Myers CE, Meuer SM, Gangnon RE, Sivakumaran TA, Iyengar SK, Lee KE, Klein BE (2013) Risk alleles in CFH and ARMS2 and the long-term natural history of age-related macular degeneration: the Beaver Dam Eye Study. JAMA Ophthalmol 131:383–392. https://doi.org/10.1001/jamaophthalmol.2013.713 CrossRefPubMedPubMedCentral

13.

Sundaresan P, Vashist P, Ravindran RD, Shanker A, Nitsch D, Nonyane BA, Smeeth L, Chakravarthy U, Fletcher AE (2012) Polymorphisms in ARMS2/HTRA1 and complement genes and age-related macular degeneration in India: findings from the INDEYE study. Invest Ophthalmol Vis Sci 53:7492–7497. https://doi.org/10.1167/iovs.12-10073 CrossRefPubMedPubMedCentral

14.

Nakata I, Yamashiro K, Kawaguchi T, Nakanishi H, Akagi-Kurashige Y, Miyake M, Tsujikawa A, Yamada R, Matsuda F, Yoshimura N, Nagahama Study Group (2015) Calcium, ARMS2 genotype, and Chlamydia pneumoniae infection in early age-related macular degeneration: a multivariate analysis from the Nagahama study. Sci Rep 5:9345. https://doi.org/10.1038/srep09345 CrossRefPubMedPubMedCentral

15.

Sakurada Y, Kubota T, Imasawa M, Mabuchi F, Tateno Y, Tanabe N, Iijima H (2011) Role of complement factor H I62V and age-related maculopathy susceptibility 2 A69S variants in the clinical expression of polypoidal choroidal vasculopathy. Ophthalmology 118:1402–1407. https://doi.org/10.1016/j.ophtha.2010.12.010 PubMed

16.

Miyake M, Yamashiro K, Tamura H, Kumagai K, Saito M, Sugahara-Kuroda M, Yoshikawa M, Oishi M, Akagi-Kurashige Y, Nakata I, Nakanishi H, Gotoh N, Oishi A, Matsuda F, Yamada R, Khor CC, Kurimoto Y, Sekiryu T, Tsujikawa A, Yoshimura N (2015) The contribution of genetic architecture to the 10-year incidence of age-related macular degeneration in the fellow eye. Invest Ophthalmol Vis Sci 56:5353–5361. https://doi.org/10.1167/iovs.14-16020 CrossRefPubMed

17.

Tateno Y, Sakurada Y, Yoneyama S, Kikushima W, Mabuchi F, Sugiyama A, Tanabe N, Kubota T, Iijima H (2016) Risk factors for second eye involvement in eyes with unilateral polypoidal choroidal vasculopathy. Ophthalmic Genet 37:177–182. https://doi.org/10.3109/13816810.2015.1020557 CrossRefPubMed

18.

Khan KN, Mahroo OA, Khan RS, Mohamed MD, McKibbin M, Bird A, Michaelides M, Tufail A, Moore AT (2016) Differentiating drusen: Drusen and drusen-like appearances associated with ageing, age-related macular degeneration, inherited eye disease and other pathological processes. Prog Retin Eye Res 53:70–106. https://doi.org/10.1016/j.preteyeres.2016.04.008 CrossRefPubMed

19.

Hata M, Yamashiro K, Ooto S, Oishi A, Tamura H, Miyata M, Ueda-Arakawa N, Takahashi A, Tsujikawa A, Yoshimura N (2017) Intraocular vascular endothelial growth factor levels in pachychoroid neovasculopathy and neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 58:292–298. https://doi.org/10.1167/iovs.16-20967 CrossRefPubMed

20.

Pang CE, Freund KB (2015) Pachychoroid neovasculopathy. Retina 35:1–9. https://doi.org/10.1097/IAE.0000000000000331 CrossRefPubMed

21.

Miyake M, Ooto S, Yamashiro K, Takahashi A, Yoshikawa M, Akagi-Kurashige Y, Ueda-Arakawa N, Oishi A, Nakanishi H, Tamura H, Tsujikawa A, Yoshimura N (2015) Pachychoroid neovasculopathy and age-related macular degeneration. Sci Rep 5:16204. https://doi.org/10.1038/srep16204 CrossRefPubMedPubMedCentral

22.

Kikushima W, Sakurada Y, Yoneyama S, Sugiyama A, Tanabe N, Kume A, Mabuchi F, Iijima H (2017) Incidence and risk factors of retreatment after three-monthly aflibercept therapy for exudative age-related macular degeneration. Sci Rep 7:44020. https://doi.org/10.1038/srep44020 CrossRefPubMedPubMedCentral

Title: AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration
Authors: Yoichi Sakurada
Wataru Kikushima
Atsushi Sugiyama
Seigo Yoneyama
Naohiko Tanabe
Mio Matsubara
Hiroyuki Iijima
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 1/2018
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-017-3847-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

AREDS simplified severity scale as a predictive factor for response to aflibercept therapy for typical neovascular age-related macular degeneration

Abstract

Purpose

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2018

Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment

Biocompatibility of intravitreal injection of human mesenchymal stem cells in immunocompetent rabbits

Potential selection bias in candidates for stereotactic radiotherapy for neovascular AMD

DEX implant intravitreal injection, sustained intraocular hypertension, and steroid-induced glaucoma in patients with no risk factors

Quantitative changes in flow density in patients with adult-onset foveomacular vitelliform dystrophy: an OCT angiography study

Estimated incidence of high altitude retinal hemorrhages